Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Safinamide, sold under the brand name Xadago among others, is a medication used as treatment for Parkinson's disease with "off" episodes; it has multiple modes of action, including the inhibition of monoamine oxidase B.
The analysis highlights History, Applications, Research and Standards as prominent areas in the source structure around Safinamide.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Explore different angles and find fresh ideas to shape your next piece of content.
Search suggestions related to this topic. Open a question to research it further; suggestions are not verified answers.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
You can skip this section if you’re here for content ideas and keyword inspiration.
The extracted context around Safinamide shows recurring relationship patterns in the source. For example, Safinamide → Farmitalia-Carlo Erba, In October, Merck, Merck KGaA, Merck-Serono, Newron, Newron Pharmaceuticals, Pharmacia, Phase III, Upjohn Another extracted example is Safinamide → ABCG2, Another, BCRP, CYP, CYP3A4, MAO, P450, SNRIs, SSRIs. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
drug effects action drugs monoamine oxidase approved studies medication metabolism people clinical found newron used episodes european interactions inhibitor reuptake
TTTA extracted 77 structured relationships around Safinamide. Examples in this analysis include Safinamide → 3D model (JSmol) → Interactive image and Safinamide → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Safinamide | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Safinamide | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Safinamide | ATC code | N04BD03 (WHO) | 1.00 | infobox |
| Safinamide | Bioavailability | 95% | 1.00 | infobox |
| Safinamide | CAS Number | 133865-89-1 Y | 1.00 | infobox |
| Safinamide | CAS Number | mesylate: 202825-46-5 | 1.00 | infobox |
| Safinamide | ChEBI | CHEBI:134718 | 1.00 | infobox |
| Safinamide | ChEMBL | ChEMBL396778 Y | 1.00 | infobox |
| Safinamide | ChEMBL | mesylate: ChEMBL48582 | 1.00 | infobox |
| Safinamide | ChemSpider | 116349 Y | 1.00 | infobox |
| Safinamide | CompTox Dashboard (EPA) | DTXSID601010282 | 1.00 | infobox |
| Safinamide | Drug class | Reversible monoamine oxidase B inhibitor, Serotonin-dopamine reuptake inhibitor, Antiparkinsonian | 1.00 | infobox |
| Safinamide | DrugBank | DB06654 Y | 1.00 | infobox |
| Safinamide | ECHA InfoCard | 100.120.167 | 1.00 | infobox |
| Safinamide | Elimination half-life | 20–30 hrs | 1.00 | infobox |
| Safinamide | Excretion | 76% Kidney, 1.5% faeces | 1.00 | infobox |
| Safinamide | Formula | C17H19FN2O2 | 1.00 | infobox |
| Safinamide | IUPHAR/BPS | 8291 | 1.00 | infobox |
| Safinamide | KEGG | D10158 Y | 1.00 | infobox |
| Safinamide | KEGG | mesylate: D10191 Y | 1.00 | infobox |
| Safinamide | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Safinamide | Legal status | CA: ℞-only | 1.00 | infobox |
| Safinamide | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Safinamide | Legal status | US: ℞-only | 1.00 | infobox |
| Safinamide | Legal status | EU: Rx-only | 1.00 | infobox |
| Safinamide | Metabolism | Amidases, glucuronidation | 1.00 | infobox |
| Safinamide | Molar mass | 302.349 g·mol−1 | 1.00 | infobox |
| Safinamide | Other names | EMD-1195686, PNU-15774E; (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl] methylamino]propanamide | 1.00 | infobox |
| Safinamide | Pregnancy category | Fetal malformations in animal studies | 1.00 | infobox |
| Safinamide | Protein binding | 88–90% | 1.00 | infobox |
The concept neighborhoods around Safinamide bring nearby vocabulary together. In this analysis, examples include Acid, Episodes and Inhibitor. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Safinamide, one of the stronger structural bridges in this analysis connects Safinamide with Pharmacology. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Safinamide to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Applications, Research & Standards, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Safinamide · EN edition · Analysis: TopicsToTalkAbout
